A Carreras1, S X Zhang1, E Peris1, Z Qiao1, Y Wang1, I Almendros1, D Gozal1. 1. Section of Pediatric Sleep Medicine, Department of Pediatrics, Comer Children's Hospital, Pritzker School of Medicine, University of Chicago, Chicago, IL, USA.
Abstract
BACKGROUND: Sleep fragmentation (SF) increases food intake and the risk of obesity, and recruits macrophages to visceral white adipose tissue (VWAT) promoting tissue inflammation and insulin resistance. Administration of resveratrol (Resv) has been associated with significant improvements in high-fat diet-induced obesity, inflammation and insulin resistance. METHODS: Male mice were subjected to SF or sleep control conditions for 8 weeks, and treated with either Resv or vehicle (Veh). Fasting plasma levels of glucose, insulin and leptin were obtained and VWAT insulin sensitivity tests were performed (phosphorylated AKT/total AKT), along with flow-cytometric assessments for VWAT macrophages (M1 and M2) and T-cell lymphocytes (CD4+, CD8+ and T regulatory cell (Treg)). RESULTS: SF-Veh and SF-Resv mice showed increased food consumption and weight gain. However, although SF-Veh mice exhibited increased fasting insulin and leptin levels, and reduced VWAT p-AKT/AKT responses to insulin, such alterations were abrogated in SF-Resv-treated mice. Increases in M1, reduced M2 counts and increased tumor necrosis factor-α release emerged in SF-Veh macrophages compared with all other three groups. Similarly, increased CD8+ and reduced Treg lymphocyte counts were apparent in SF-Veh. CONCLUSIONS: Resveratrol does not reverse the SF-induced increases in food intake and weight gain, but markedly attenuates VWAT inflammation and insulin resistance, thereby providing a potentially useful adjunctive therapy in the context of sleep disorders manifesting metabolic morbidity.
BACKGROUND: Sleep fragmentation (SF) increases food intake and the risk of obesity, and recruits macrophages to visceral white adipose tissue (VWAT) promoting tissue inflammation and insulin resistance. Administration of resveratrol (Resv) has been associated with significant improvements in high-fat diet-induced obesity, inflammation and insulin resistance. METHODS: Male mice were subjected to SF or sleep control conditions for 8 weeks, and treated with either Resv or vehicle (Veh). Fasting plasma levels of glucose, insulin and leptin were obtained and VWAT insulin sensitivity tests were performed (phosphorylated AKT/total AKT), along with flow-cytometric assessments for VWAT macrophages (M1 and M2) and T-cell lymphocytes (CD4+, CD8+ and T regulatory cell (Treg)). RESULTS: SF-Veh and SF-Resvmice showed increased food consumption and weight gain. However, although SF-Veh mice exhibited increased fasting insulin and leptin levels, and reduced VWAT p-AKT/AKT responses to insulin, such alterations were abrogated in SF-Resv-treated mice. Increases in M1, reduced M2 counts and increased tumor necrosis factor-α release emerged in SF-Veh macrophages compared with all other three groups. Similarly, increased CD8+ and reduced Treg lymphocyte counts were apparent in SF-Veh. CONCLUSIONS:Resveratrol does not reverse the SF-induced increases in food intake and weight gain, but markedly attenuates VWAT inflammation and insulin resistance, thereby providing a potentially useful adjunctive therapy in the context of sleep disorders manifesting metabolic morbidity.
Authors: Kevin J Pearson; Joseph A Baur; Kaitlyn N Lewis; Leonid Peshkin; Nathan L Price; Nazar Labinskyy; William R Swindell; Davida Kamara; Robin K Minor; Evelyn Perez; Hamish A Jamieson; Yongqing Zhang; Stephen R Dunn; Kumar Sharma; Nancy Pleshko; Laura A Woollett; Anna Csiszar; Yuji Ikeno; David Le Couteur; Peter J Elliott; Kevin G Becker; Placido Navas; Donald K Ingram; Norman S Wolf; Zoltan Ungvari; David A Sinclair; Rafael de Cabo Journal: Cell Metab Date: 2008-07-03 Impact factor: 27.287
Authors: Gina B Di Gregorio; Aiwei Yao-Borengasser; Neda Rasouli; Vijayalakshmi Varma; Tong Lu; Leslie M Miles; Gouri Ranganathan; Charlotte A Peterson; Robert E McGehee; Philip A Kern Journal: Diabetes Date: 2005-08 Impact factor: 9.461
Authors: Deepti Nair; Shelley X L Zhang; Vijay Ramesh; Fahed Hakim; Navita Kaushal; Yang Wang; David Gozal Journal: Am J Respir Crit Care Med Date: 2011-08-25 Impact factor: 21.405
Authors: S W van den Berg; E H J Jansen; M Kruijshoop; P K Beekhof; E Blaak; C J van der Kallen; M M van Greevenbroek; E J M Feskens Journal: Diabet Med Date: 2008-02 Impact factor: 4.359
Authors: Carla S Möller-Levet; Simon N Archer; Giselda Bucca; Emma E Laing; Ana Slak; Renata Kabiljo; June C Y Lo; Nayantara Santhi; Malcolm von Schantz; Colin P Smith; Derk-Jan Dijk Journal: Proc Natl Acad Sci U S A Date: 2013-02-25 Impact factor: 11.205
Authors: Emily L Rossi; Subreen A Khatib; Steven S Doerstling; Laura W Bowers; Melissa Pruski; Nikki A Ford; Randolph D Glickman; Mengmeng Niu; Peiying Yang; Zhengrong Cui; John DiGiovanni; Stephen D Hursting Journal: Mol Carcinog Date: 2017-12-01 Impact factor: 4.784